SynthesisBMC medicine2025
The multimodal neuroimaging signatures and gene expression profiles for adverse childhood experiences.
Synthesis in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A new approach for understanding the association between chronic stress in childhood and psychotic symptoms in schizophrenia patients from mediating role of lncRNA.Schizophrenia (Heidelberg, Germany) · 2026Article
- Neurodevelopmental disorders in children: the role of MRI in early detection and intervention planning.Frontiers in neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAdverse childhood experiences (ACEs) have been considered significant drivers of negative mental health and cognitive outcomes. However, identifying clear neurobiological signatures of ACEs has been challenging due to limited sample sizes, participant heterogeneity, and methodological variability.
methodsA whole-brain meta-analysis was conducted to identify functional, structural, and overlapping brain alterations in ACEs-exposed individuals compared to unexposed controls, using a large sample (functional analysis: 63 studies, 3549 participants; structural analysis: 38 studies, 2919 participants). Subgroup analyses were performed based on age, adversity type, diagnostic status, and functional magnetic resonance imaging task domains, providing a more nuanced aspect of ACEs' effect on neurodevelopment. Furthermore, the BrainMap-derived task activation maps, atlas-based nuclear imaging-derived neurotransmitter maps, and postmortem gene expression profiles were integrated to examine spatial correlations between ACEs-related brain abnormalities and downstream behavioral processes, disease domains, and upstream receptor/transporter distributions and gene expression.
resultsACEs-exposed individuals exhibited significantly increased functional activity in the amygdala, increased gray matter volume (GMV) in the parahippocampal gyrus, and reduced GMV in the inferior frontal gyrus and supramarginal gyrus, with overlapping abnormalities observed in the parahippocampal gyrus. Subgroup analyses revealed distinct brain alterations. Furthermore, specific associations were identified between structural alterations and the distribution of dopaminergic, serotonergic, and GABAergic neurotransmitter systems. Enrichment analyses further emphasized the profound impact of ACEs on neurodevelopment, immunometabolism, and psychopathological trajectories.
conclusionsThese findings characterize the neural substrates of ACEs, providing valuable insights into their impact on neurodevelopment and suggesting potential targets for ACEs-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.